India pharma & healthcare deals hit $13.9 bn in Q2 2026, M&A at all-time high
Synopsis
India's pharma and healthcare sector quietly set an M&A record in Q2 2026 — $13.2 billion across 35 deals, with outbound transactions accounting for 96 per cent of that value. Strip out the landmark $11.8 billion overseas acquisition and deal values still grew 12 per cent. The message is clear: Indian pharma is no longer buying for scale — it is buying for science, specialty, and global reach.
Key Takeaways
India's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 2026 , according to Grant Thornton Bharat .
M&A activity hit an all-time high at $13.2 billion across 35 deals , up 17 per cent in volume quarter-on-quarter.
Outbound transactions accounted for 96 per cent of total M&A value, led by the largest-ever overseas acquisition by an Indian pharma company at $11.8 billion .
Excluding that single deal, overall deal values still rose 12 per cent over the previous quarter.
Pharma and biotech led sectorally with 23 deals worth $12.7 billion .
Public markets saw two IPOs raising $58 million and two QIPs raising $161 million .
India's pharma and healthcare sector logged 65 deals worth $13.9 billion in Q2 2026, even as overall transaction volumes dipped, according to a report released by Grant Thornton Bharat on 23 July 2026. Despite the moderation in deal count, aggregate values held firm — and excluding the quarter's standout $11.8 billion transaction, which was the largest overseas acquisition ever by an Indian pharmaceutical company, deal values still climbed 12 per cent over the previous quarter.
M&A Activity Reaches All-Time High
Mergers and acquisitions were the dominant force this quarter, with 35 deals worth $13.2 billion — transaction volumes rising 17 per cent quarter-on-quarter and values touching an all-time high. Outbound transactions alone accounted for 96 per cent of total M&A value, underscoring the accelerating global ambitions of Indian pharmaceutical companies as they chase specialty portfolios, innovation capabilities, and a stronger foothold in regulated international markets.
Inbound activity also showed signs of revival, with four inbound transactions recorded during the quarter. Domestic deals continued to account for the majority of M&A volumes, maintaining their structural importance even as cross-border deals grabbed headline value.
Pharma and Biotech Lead by a Wide Margin
Sectorally, pharma and biotech dominated the quarter with 23 deals worth $12.7 billion, driven by strategic acquisitions spanning specialty pharma, biologics, active pharmaceutical ingredients (APIs), established brands, and therapeutic portfolios. The concentration of value in this sub-segment signals a deliberate industry pivot toward differentiated, science-led assets rather than volume-driven plays.
Public Market Activity Stays Steady
Public market transactions remained measured but consistent. Two IPOs collectively raised $58 million, while two Qualified Institutional Placements (QIPs) brought in $161 million, providing an alternative capital route for listed healthcare firms looking to fund expansion without diluting strategic control.
What Industry Leaders Are Saying
Bhanu Prakash Kalmath S J, Partner and Healthcare Industry Leader at Grant Thornton Bharat, said the quarter reflects a clear strategic shift. 'Indian companies are increasingly pursuing acquisitions that strengthen specialty portfolios, expand global market access and build differentiated capabilities rather than scale alone,' he noted.
Kalmath added that investor interest remains firmly anchored in innovation-led healthcare businesses, particularly across AI-enabled care, genomics, oncology, and advanced diagnostics. 'As healthcare delivery and life sciences continue to evolve, we expect strategic acquisitions and targeted investments to remain the key drivers of deal activity,' he said.
With outbound M&A at record levels and investor appetite tilting toward high-differentiation assets, India's pharma deal pipeline heading into the second half of 2026 looks structurally robust — contingent on global regulatory environments and currency dynamics remaining stable.
Point of View
Which is the more telling signal. Indian pharma is no longer simply buying revenue; it is buying capabilities in biologics, genomics, and AI-enabled care. The 96 per cent outbound share of M&A value is a structural statement: domestic consolidation has largely run its course, and the next phase of value creation is being written in regulated markets abroad. The risk is execution — large cross-border integrations in pharma are notoriously complex, and India's track record on post-merger value retention is mixed. Investor enthusiasm for innovation-led assets is well-placed, but the sector's ability to absorb and operationalise these acquisitions will define whether Q2 2026 is remembered as a turning point or a peak.
NationPress
23 Jul 2026
Frequently Asked Questions
How many pharma and healthcare deals were recorded in India in Q2 2026?
India's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 2026, according to a Grant Thornton Bharat report released on 23 July 2026. Despite lower deal volumes compared to prior periods, aggregate values remained resilient.
What drove M&A values to an all-time high in Q2 2026?
M&A activity reached an all-time high of $13.2 billion across 35 deals, driven primarily by outbound transactions that accounted for 96 per cent of total M&A value. The quarter's standout was a $11.8 billion overseas acquisition — the largest ever by an Indian pharmaceutical company.
Which sector led deal activity in Q2 2026?
Pharma and biotech led the quarter with 23 deals worth $12.7 billion, driven by acquisitions in specialty pharma, biologics, APIs, established brands, and therapeutic portfolios.
What was the public market activity in India's healthcare sector in Q2 2026?
Public market activity was steady, with two IPOs raising $58 million and two QIPs raising $161 million during the quarter.
What investment themes are attracting capital in Indian healthcare?
According to Grant Thornton Bharat, investor interest is focused on innovation-led businesses in AI-enabled care, genomics, oncology, and advanced diagnostics. Strategic acquisitions and targeted investments are expected to remain the primary drivers of deal activity going forward.
